These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6430312)

  • 21. Comparative studies with Fluosol, Dextran, their mixture, or autologous blood in experimental hypovolemic shock.
    Madjidi A; Beisbarth H; Frey R
    Prog Clin Biol Res; 1983; 122():391-7. PubMed ID: 6192451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High oxygen delivery and extraction by perfluorocarbon-primed extracorporeal membrane oxygenation do not prevent anaerobic metabolism in rabbits.
    Iwao Y; Tashiro M; Iijima T; Masuda J; Sankawa H
    J Pediatr Surg; 1998 Mar; 33(3):422-7. PubMed ID: 9537551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of oxygenation on the 19F spin-lattice relaxation rates of fluosol-DA.
    Reid RS; Koch CJ; Castro ME; Lunt JA; Treiber EO; Boisvert DJ; Allen PS
    Phys Med Biol; 1985 Jul; 30(7):677-86. PubMed ID: 4023055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients.
    Stefaniszyn HJ; Wynands JE; Salerno TA
    J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transperitoneal oxygenation with fluorocarbons.
    Klein J; Faithfull NS; Salt PJ; Trouwborst A
    Anesth Analg; 1986 Jul; 65(7):734-8. PubMed ID: 3717613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes of hemodynamics and O2 transport associated with the perfluorochemical blood substitute, Fluosol-DA.
    Nishimura N; Sugi T
    Crit Care Med; 1984 Jan; 12(1):36-8. PubMed ID: 6690204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased radiosensitivity of tumors by perfluorochemicals and carbogen.
    Song CW; Zhang WL; Pence DM; Lee I; Levitt SH
    Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1833-6. PubMed ID: 3930442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transabdominal oxygenation using perfluorocarbons.
    Chiba T; Harrison MR; Ohkubo T; Rollins MD; Albanese CT; Jennings RW
    J Pediatr Surg; 1999 May; 34(5):895-900; discussion 900-1. PubMed ID: 10359202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of haemodilution with fluorocarbons or dextran on oxygen tensions in the acutely ischaemic myocardium.
    Faithfull NS; Erdmann W; Fennema M; Kok A
    Br J Anaesth; 1986 Sep; 58(9):1031-40. PubMed ID: 2428389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Red blood cell substitutes and artificial blood.
    Bowman RJ
    Hum Pathol; 1983 Mar; 14(3):218-20. PubMed ID: 6832769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
    Teicher BA; Herman TS; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inadequate subendocardial oxygen delivery during perfluorocarbon perfusion in a canine model of ischemia.
    Christensen CW; Reeves WC; Lassar TA; Schmidt DH
    Am Heart J; 1988 Jan; 115(1 Pt 1):30-7. PubMed ID: 3336983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute.
    Lane TA; Lamkin GE
    Blood; 1986 Aug; 68(2):351-4. PubMed ID: 3524707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The place for using erythrocyte substitutes in hemodilution: fluosol-DA and polymerized pyridoxylated hemoglobin].
    Vigneron C; Labrude P; Dellacherie E
    Ann Fr Anesth Reanim; 1986; 5(3):260-8. PubMed ID: 3535579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.
    Kerins DM
    Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713
    [No Abstract]   [Full Text] [Related]  

  • 36. Stability of perfluorocarbon blood substitutes determined by sedimentation field-flow fractionation.
    Yang FS; Caldwell KD; Giddings JC; Astle L
    Anal Biochem; 1984 May; 138(2):488-94. PubMed ID: 6742424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with Fluosol-DA.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Moss GS
    Prog Clin Biol Res; 1983; 122():331-42. PubMed ID: 6878375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases.
    Mitsuno T; Ohyanagi H; Naito R
    Ann Surg; 1982 Jan; 195(1):60-9. PubMed ID: 7034658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maternal and fetal effects of exchange transfusion with a red blood cell substitute.
    Cefalo RC; Seeds JW; Proctor HJ; Baker VV
    Am J Obstet Gynecol; 1984 Apr; 148(7):859-67. PubMed ID: 6711627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients.
    Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.